AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT108.33-0.46 (-0.42%) ▼|ACN186.72-6.40 (-3.31%) ▼|ADBE266.51-19.24 (-6.73%) ▼|AMAT454.71+18.80 (+4.31%) ▲|AMD477.57+21.41 (+4.69%) ▲|AMGN437.23-6.89 (-1.55%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN258.51-0.39 (-0.15%) ▼|AVGO357.90+0.74 (+0.21%) ▲|AXP326.16-3.66 (-1.11%) ▼|BA212.25+1.74 (+0.83%) ▲|BAC62.68-0.04 (-0.06%) ▼|BKNG193.29-1.84 (-0.94%) ▼|BLK1,122.29-3.86 (-0.34%) ▼|BMY66.82-1.27 (-1.87%) ▼|BNY164.84+0.51 (+0.31%) ▲|BRK-B506.03-2.10 (-0.41%) ▼|C137.72-0.42 (-0.30%) ▼|CAT813.94+13.80 (+1.72%) ▲|CL88.77-1.32 (-1.47%) ▼|CMCSA26.49-0.16 (-0.60%) ▼|COF219.60-0.90 (-0.41%) ▼|COP134.26-1.46 (-1.08%) ▼|COST915.74-9.67 (-1.04%) ▼|CRM259.23-5.20 (-1.97%) ▼|CSCO109.20+0.59 (+0.54%) ▲|CVS96.74-0.46 (-0.47%) ▼|CVX208.60-2.72 (-1.29%) ▼|DE693.53-0.88 (-0.13%) ▼|DHR207.66-3.37 (-1.60%) ▼|DIS105.31-1.85 (-1.73%) ▼|DUK120.22-1.18 (-0.97%) ▼|EMR152.82+2.61 (+1.74%) ▲|FDX322.52-1.79 (-0.55%) ▼|GD359.39-6.48 (-1.77%) ▼|GE337.12+3.64 (+1.09%) ▲|GEV941.95+0.11 (+0.01%) ▲|GILD151.00-0.23 (-0.15%) ▼|GM87.76+0.72 (+0.83%) ▲|GOOG335.31-3.77 (-1.11%) ▼|GOOGL338.46-3.80 (-1.11%) ▼|GS1,038.61+0.68 (+0.07%) ▲|HD321.05+2.98 (+0.94%) ▲|HON209.61+1.98 (+0.95%) ▲|IBM234.89+0.18 (+0.08%) ▲|INTC95.80+4.13 (+4.51%) ▲|INTU332.70-11.60 (-3.37%) ▼|ISRG366.70-3.13 (-0.85%) ▼|JNJ275.23-3.20 (-1.15%) ▼|JPM358.64-3.42 (-0.94%) ▼|KO88.07-0.74 (-0.83%) ▼|LIN477.57-4.62 (-0.96%) ▼|LLY1,149.36-10.24 (-0.88%) ▼|LMT525.28-7.67 (-1.44%) ▼|LOW204.45+2.55 (+1.26%) ▲|LRCX307.65+14.99 (+5.12%) ▲|MA579.21-6.50 (-1.11%) ▼|MCD255.69-3.94 (-1.52%) ▼|MDLZ61.28-0.17 (-0.28%) ▼|MDT94.17+1.07 (+1.15%) ▲|META616.77+6.09 (+1.00%) ▲|MMM168.56+0.25 (+0.15%) ▲|MO68.88-0.61 (-0.88%) ▼|MRK150.33-2.01 (-1.32%) ▼|MS217.72+0.57 (+0.26%) ▲|MSFT499.70-10.42 (-2.04%) ▼|MU1,016.59+58.43 (+6.10%) ▲|NEE83.43-0.63 (-0.75%) ▼|NFLX78.25-4.42 (-5.35%) ▼|NKE38.40-0.37 (-0.95%) ▼|NOW141.26-4.33 (-2.97%) ▼|NVDA230.36+1.91 (+0.84%) ▲|ORCL158.78+4.74 (+3.08%) ▲|PEP137.63-0.91 (-0.66%) ▼|PFE28.45-0.36 (-1.25%) ▼|PG146.44-0.48 (-0.33%) ▼|PLTR174.33-8.20 (-4.49%) ▼|PM182.53-3.64 (-1.96%) ▼|QCOM168.74+0.17 (+0.10%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO613.78-4.65 (-0.75%) ▼|TMUS181.52-6.50 (-3.46%) ▼|TSLA354.08-22.29 (-5.92%) ▼|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT108.33-0.46 (-0.42%) ▼|ACN186.72-6.40 (-3.31%) ▼|ADBE266.51-19.24 (-6.73%) ▼|AMAT454.71+18.80 (+4.31%) ▲|AMD477.57+21.41 (+4.69%) ▲|AMGN437.23-6.89 (-1.55%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN258.51-0.39 (-0.15%) ▼|AVGO357.90+0.74 (+0.21%) ▲|AXP326.16-3.66 (-1.11%) ▼|BA212.25+1.74 (+0.83%) ▲|BAC62.68-0.04 (-0.06%) ▼|BKNG193.29-1.84 (-0.94%) ▼|BLK1,122.29-3.86 (-0.34%) ▼|BMY66.82-1.27 (-1.87%) ▼|BNY164.84+0.51 (+0.31%) ▲|BRK-B506.03-2.10 (-0.41%) ▼|C137.72-0.42 (-0.30%) ▼|CAT813.94+13.80 (+1.72%) ▲|CL88.77-1.32 (-1.47%) ▼|CMCSA26.49-0.16 (-0.60%) ▼|COF219.60-0.90 (-0.41%) ▼|COP134.26-1.46 (-1.08%) ▼|COST915.74-9.67 (-1.04%) ▼|CRM259.23-5.20 (-1.97%) ▼|CSCO109.20+0.59 (+0.54%) ▲|CVS96.74-0.46 (-0.47%) ▼|CVX208.60-2.72 (-1.29%) ▼|DE693.53-0.88 (-0.13%) ▼|DHR207.66-3.37 (-1.60%) ▼|DIS105.31-1.85 (-1.73%) ▼|DUK120.22-1.18 (-0.97%) ▼|EMR152.82+2.61 (+1.74%) ▲|FDX322.52-1.79 (-0.55%) ▼|GD359.39-6.48 (-1.77%) ▼|GE337.12+3.64 (+1.09%) ▲|GEV941.95+0.11 (+0.01%) ▲|GILD151.00-0.23 (-0.15%) ▼|GM87.76+0.72 (+0.83%) ▲|GOOG335.31-3.77 (-1.11%) ▼|GOOGL338.46-3.80 (-1.11%) ▼|GS1,038.61+0.68 (+0.07%) ▲|HD321.05+2.98 (+0.94%) ▲|HON209.61+1.98 (+0.95%) ▲|IBM234.89+0.18 (+0.08%) ▲|INTC95.80+4.13 (+4.51%) ▲|INTU332.70-11.60 (-3.37%) ▼|ISRG366.70-3.13 (-0.85%) ▼|JNJ275.23-3.20 (-1.15%) ▼|JPM358.64-3.42 (-0.94%) ▼|KO88.07-0.74 (-0.83%) ▼|LIN477.57-4.62 (-0.96%) ▼|LLY1,149.36-10.24 (-0.88%) ▼|LMT525.28-7.67 (-1.44%) ▼|LOW204.45+2.55 (+1.26%) ▲|LRCX307.65+14.99 (+5.12%) ▲|MA579.21-6.50 (-1.11%) ▼|MCD255.69-3.94 (-1.52%) ▼|MDLZ61.28-0.17 (-0.28%) ▼|MDT94.17+1.07 (+1.15%) ▲|META616.77+6.09 (+1.00%) ▲|MMM168.56+0.25 (+0.15%) ▲|MO68.88-0.61 (-0.88%) ▼|MRK150.33-2.01 (-1.32%) ▼|MS217.72+0.57 (+0.26%) ▲|MSFT499.70-10.42 (-2.04%) ▼|MU1,016.59+58.43 (+6.10%) ▲|NEE83.43-0.63 (-0.75%) ▼|NFLX78.25-4.42 (-5.35%) ▼|NKE38.40-0.37 (-0.95%) ▼|NOW141.26-4.33 (-2.97%) ▼|NVDA230.36+1.91 (+0.84%) ▲|ORCL158.78+4.74 (+3.08%) ▲|PEP137.63-0.91 (-0.66%) ▼|PFE28.45-0.36 (-1.25%) ▼|PG146.44-0.48 (-0.33%) ▼|PLTR174.33-8.20 (-4.49%) ▼|PM182.53-3.64 (-1.96%) ▼|QCOM168.74+0.17 (+0.10%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO613.78-4.65 (-0.75%) ▼|TMUS181.52-6.50 (-3.46%) ▼|TSLA354.08-22.29 (-5.92%) ▼|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|
24.1 C
New York
Tuesday, September 8, 2026

Tag: drug

newssourceFORcompanyinformationcontent1releasesmarket

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocrinology. GALWAY, Ireland and...

Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin

Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes CHICAGO, June 20, 2025 /PRNewswire/ -- Findings from two studies...

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

Doctor Discount Network Provides Essential Information for Safe Online Phentermine Purchases Amidst Growing Concerns

ELLENTON, Fla., June 20, 2025 /PRNewswire/ -- The convenience of online pharmacies has made them a popular source for prescription medications, including Phentermine, a...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the company’s common stock to 26 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCLACEL PHARMACEUTICALS ANNOUNCES $3 MILLION PRIVATE PLACEMENT OFFERING OF CONVERTIBLE PREFERRED STOCK

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements

NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Virtual webinar on June 23, 2025 at 8:00 am ET 
Virtual webinar on June 23, 2025 at 8:00 am ET

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference

HERZLIYA, Israel and CALGARY, AB, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a...

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference

HERZLIYA, Israel and CALGARY, AB, June 20, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a...

PharmAla Files Preliminary Base Shelf Prospectus

Pharmala files short form prospectus

The American Diabetes Association Demonstrates Its Commitment to Curbing the Obesity Epidemic with Obesity Standards of Care

Symposium previews new content for Standards of Care in Overweight and Obesity, designed to improve patient care and outcomes CHICAGO, June 20, 2025 /PRNewswire/...

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO,...

SeaStar Medical Announces Pricing of Up to $8 Million Public Offering

$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants 
$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers